Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Report>Interim>Q1

Q1

  • Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

    23 May 2025

  • Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

    17 May 2024

  • Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

    19 May 2023

  • Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

    29 July 2022

  • Interim report for first quarter 2021, 1 January – 31 March 2021

    21 May 2021

  • Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.

    10 June 2020

  • INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

    24 May 2019

  • INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 31st March 2018

    7 June 2018

  • Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016

    3 May 2016

  • Interim Report for Kancera AB (publ) Q1 2015 January 1 – March 31, 2015

    22 May 2015

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications